Loading stock data…
Aquestive Therapeutics, Inc. (AQST)
$5.34-0.01 (-0.19%)
Pre-Market$5.38+0.04 (+0.75%)· Last close Sep 4
Aquestive Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aquestive Therapeutics, Inc. in the Healthcare sector is trading at $5.34 with a market capitalization of $592M. Wall Street consensus targets $9.33 (9 analysts), implying a +74.8% move over the next 12 months. The stock is currently 29% below its 52-week high of $7.55, remaining 19.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +74.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14.45M↑ | $13.02M↑ | $12.81M↑ | $10.00M↑ | $8.72M |
| Gross Profit | $10.98M↑ | $7.18M↓ | $8.30M↑ | $5.44M↑ | $5.07M |
| Operating Income | -$4.20M↑ | -$28.84M↓ | -$11.48M↓ | -$11.37M↑ | -$19.36M |
| Net Income | -$8.06M↑ | -$31.86M↓ | -$15.45M↓ | -$13.55M↑ | -$22.93M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of b...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$592.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
202.36%
Volume
Today's trading volume
2.12M
Recent News
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
On August 11, Aquestive Therapeutics (NASDAQ:AQST) reported second-quarter 2026 results and said it remains on track to resubmit its Anaphylm epinephrine film to the FDA in the third quarter of 2026. That single sentence carries the whole story here. A company living and dying by one product candidate just cleared the studies standing between it […]
Aquestive (AQST) Q2 2026 Earnings Call Transcript
Revenue grew 38% year-over-year to $13.8 million as Anaphylm resubmission nears.
Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ...
Company advances toward Q3 NDA resubmission with improved human factors data, while total revenue climbs to $13.8 million and adjusted EBITDA loss narrows to $5.2 million.
Aquestive Therapeutics Q2 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis, before the end of the third quarter after completing studies requested by the U.S. Food and Drug Admini
Aquestive Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Aquestive Therapeutics, Inc.'s Q2 2026 earnings call